Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Hiddo J.L. Heerspink(University Medical Center Groningen), Toby Coates, Georgina Irish, Ulysses Diva(Korean Red Cross), Philip A. Clayton(Royal Adelaide Hospital), Bhadran Bose, Michelle N. Rheault(Columbia University Irving Medical Center), William E. Rote(Therapeutics Clinical Research), Mai Rosenberg, M Praga, Charles E. Alpers(University of Washington), Vlado Perkovic(New South Wales Department of Health), Rathika Krishnasamy, Howard Trachtman(University of Michigan), Irene L. Noronha(Universidade de São Paulo), Robert Małecki(Międzyleski Szpital Specjalistyczny w Warszawie), Bojan Jelaković(University Hospital Centre Zagreb), Muralikrishna Gangadharan, Kannaiyan S Rabindranath, Robert J. Carroll(Vanderbilt University), Brad H. Rovin(The Ohio State University Wexner Medical Center), Muh Geot Wong(FIND), Jula K. Inrig(Duke University), Marius Miglinas, Susan Crail, Jonathan Barratt(University of Leicester), Chen Au Peh(Royal Adelaide Hospital), Shilpanjali Jesudason(South Australia Pathology), Peter Hollett, Fernando Nolasco(Unidade Local de Saúde de São José), Radko Komers(University of Utah), Sadia Jahan(Royal Adelaide Hospital), Hernán Trimarchi(University of Michigan), Chii Yeap, Vladmir Tesar, Dong‐Wan Chae(Ewha Womans University), Bart Maes(AZ Delta), Shang‐Jyh Hwang(Kaohsiung Medical University), Stewart Bieler(University of Washington), Jai Radhakrishnan(Columbia University), Eric Alarmartine, Sydney Tang(Chinese University of Hong Kong), Stephen P. McDonald(Royal Adelaide Hospital), Nikhil Thyagarajan(Royal Adelaide Hospital), Jürgen Floege(RWTH Aachen University), Alex Mercer(Innovation Management Consulting Group (Sweden)), Lucia Del Vecchio(Azienda Socio Sanitaria Territoriale Lariana)
Cited by 214
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k